Currently, there are 0.70M common shares owned by the public and among those 0.63M shares have been available to trade.
The company’s stock has a 5-day price change of 44.00% and -82.26% over the past three months. RNAZ shares are trading -66.77% year to date (YTD), with the 12-month market performance down to -95.08% lower. It has a 12-month low price of $0.64 and touched a high of $66.33 over the same period. RNAZ has an average intraday trading volume of 2.61 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -39.58%, -78.19%, and -91.74% respectively.
Institutional ownership of TransCode Therapeutics Inc (NASDAQ: RNAZ) shares accounts for 26.18% of the company’s 0.70M shares outstanding.
It has a market capitalization of $0.78M and a beta (3y monthly) value of 1.40. The earnings-per-share (ttm) stands at -$265.83. Price movements for the stock have been influenced by the stock’s volatility, which stands at 31.72% over the week and 28.54% over the month.
Analysts forecast that TransCode Therapeutics Inc (RNAZ) will achieve an EPS of -3.21 for the current quarter, -1.48 for the next quarter and -4.37 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -3.21 while analysts give the company a high EPS estimate of -3.21. Comparatively, EPS for the current quarter was -627.33 a year ago. Earnings per share for the fiscal year are expected to increase by 95.41%, and 8.19% over the next financial year. EPS should grow at an annualized rate of 78.85% over the next five years, compared to -28.81% over the past 5-year period.
